Common use of COSTS AND PAYMENT SCHEDULE Clause in Contracts

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 will be US$ [**], made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ [**] - Short term stability study (2.2.3) US $ [**] - (transferred from Section 2.2.2 of Schedule B-1) Payments will be made to Abbott by Barrier as follows: - [**] - [**] - [**] - [**] - [**] ABBOTT GMBH & CO. KG BARRIER THERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 B-3 will be US$ [**], made ] make up of: - Manufacture and supply of 2 GMP batches manufacture [**] Bulk Product US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ [**] - Short term stability study (2.2.3) US $ [**] - (transferred from Section 2.2.2 of Schedule B-1) Payments will be made to Abbott by Barrier as follows: - [**] - [**] - [**] - [**] - [**] ABBOTT GMBH & COXX. KG XG BARRIER THERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh Charles T. Nomides ---------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS ByCharles T. Nomides Xxxx xx XXXXXX XXX Xx: /s/ Jon Lewis Xxxe/x/ Xxx Xewis Date: 30 September 2002 11-MAR-03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- 18 Xxxxx 0003 ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 B-4 PRE-STAGE 5 WORKPLAN FOR STAGE 31. AIM OF WORK Abbott will manufacture two batches of [**] Bulk Product to be used xxx xxchnical and analytical assessment and further manufacturing trials. The target of these trials is to [**]. Analytical testing will be carried out with the intention of defining methods of distinguishing between different batches of Bulk Product. The technical responsibilities will be described hereinafter.

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 will be US$ [**], made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ [**] - Short term stability study (2.2.3) US $ [**] - (transferred from Section 2.2.2 of Schedule B-1) Payments will be made to Abbott by Barrier as follows: - US $ [**] within 30 days of signature of this Schedule B-2, - US $ [**] on Barrier's receipt of the first GMP batch of Bulk Product from Abbott, - US $ [**] on Barrier's receipt of the second GMP batch of Bulk Product from Abbott, - US $ [**] exclusivity milestone payment (in accordance with Schedule A) on Barrier's receipt of the second GMP batch of Bulk Product from Abbott, and - US $ [**] on Barrier's receipt of the short term stability report. ABBOTT GMBH & CO. KG BARRIER THERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 B-4 will be US$ [**], ] made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ Manufacture and supply of two batches each of [**] Bulk Product US$ [**] - Short term stability study Process analysis (2.2.3Section 2.2.2) US $ US$ [**] - Development and validation of HPLC method (transferred from Section 2.2.2 of Schedule B-12.2.3) Payments will be made to Abbott by Barrier as follows: - US$ [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made by Barrier to Abbott as follows: - US$ [**] within 30 days of signature of thxx Xxxedule B-4, and - US$ [**] Barrier's receipt of Abbott's report. ABBOTT GMBH & CO. KG BARRIER THERAPEUTICSXXXXXXXXTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ---------------------------------- ----------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 24/04/03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- 24tx Xxxxx 0003 ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6)

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 B-4 will be US$ [**], ] made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ Manufacture and supply of two batches each of [**] kg Bulk Product US$ [**] - Short term stability study Process analysis (2.2.3Section 2.2.2) US $ US$ [**] - Development and validation of HPLC method (transferred from Section 2.2.2 of Schedule B-12.2.3) Payments will be made to Abbott by Barrier as follows: - US$ [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made by Barrier to Abbott as follows: - US$ [**] within 30 days of signature of this Schedule B-4, and - US$ [**] Barrier's receipt of Abbott's report. ABBOTT GMBH & CO. KG BARRIER THERAPEUTICSXXXXXXXXTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ---------------------------------- ----------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 24/04/03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 24tx Xxxxx 0003 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6)

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 B-5 will be US$ E [**], ] made up of: - Manufacture and supply Process development related to manufacture of 2 GMP NDA batches US $ (of which Part A + Part B = E[**]; Part C = E[**]) E[**] - Preparation of NDA documentation E[**] - Manufacture of six NDA batches E[**] - Process analysis E[**] - Development report E[**] Payments will be made by Barrier to Abbott as follows: - E[**] within 30 days of signature of this Schedule B-5; - E[**] on supply by Abbott of sixth NDA batch; - Milestone payment of US$[**] on Barrier's, or its nominee's, receipt of the sixth NDA batch; - E[**] on Barrier's receipt of Abbott's development report; - E[**] on completion by Abbott of prxxxxx xxvelopment Part C. ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ [**] - Short term stability study (2.2.3) US $ [**] - (transferred from Section 2.2.2 of Schedule B-1) Payments will be made to Abbott by Barrier as follows: - [**] - [**] - [**] - [**] - [**] ABBOTT GMBH & CO. KG BARRIER THERAPEUTICSTHERAPEUTIXX, INCXXC. XxBy: ppa /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh Charles T. Nomides ---------------------------------- ---------------------------------- ------------------------ Dr. Jorg Breitenbach Director, Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3SOLIQS